cor2ed
engage checkpoint medical linkedin twitter
bg

Appropriate selection of patients for 1st line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs

Appropriate selection of patients for 1st line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs

Prof Richard Finn, Dr. Mohamed Bouattour, Prof. James Harding, Dr. Choo Su Pin

This HCC CONNECT e-learning programme helps to provide an understanding of the management of patients with advanced or unresectable HCC and who could benefit from VEGFR-TKI monotherapy in first-line setting
Richard-Finn
Prof Richard Finn

Medical Oncologist

Geffen School of Medicine at UCLA

United States (US)

Portrait of Mohamed Bouattour
Dr. Mohamed Bouattour

Hepatologist and Gastroenterologist

Beaujon University Hospital

France

Portrait of James Harding
Prof. James Harding

Medical Oncologist

Memorial Sloan Kettering Cancer Center

United States (US)

Portrait of Choo Su Pin
Dr. Choo Su Pin

Medical Oncologist

Curie Oncology

Singapore

preview next

time E-learning | open 83 min |accreditation: EACCME

I agree that this educational programme:

Was valuable to me:

1/3

The international faculty for this HCC CONNECT virtual Experts Knowledge address “Appropriate selection of patients for first-line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs”. The faculty explore the profile of patients with advanced or unresectable HCC  who could benefit from VEGFR-TKI monotherapy in first-line setting, explore real-world evidence, discuss the safety profile of the monotherapies, look into the future, with the potential promising combination therapies in the treatment of HCC and also provides an update on key HCC data presented recently at ASCO GI 2022.

This accredited e-learning will provide you with an overview of selection of patients for 1st line monotherapy in HCC

  • The patient-profile who could benefit from VEGFR-TKI monotherapy 1st line in advanced or unresectable HCC
  • Real-world data with monotherapy and the implications for clinical practice
  • The safety profile of the monotherapies, be able to recognise the cause of toxicities and know the appropriate dosing strategies to manage side effects
  • A look into the future, the potential of combination therapies in the treatment of HCC

Meeting Video Chapters

00:00   Faculty and Disclaimer

00:15   Who Can Benefit from VEGFR-TKI Monotherapy Today? Prof Finn

18:38   What did we learn from the real-world data? What can we translate into clinical practice? Dr Bouattour

36:44   Treating patients with VEGFR-TKI monotherapy:
           What are the treatment related AEs and how to manage them? Prof Harding

56:06   Latest updates in HCC from ASCO GI 2022 (HIMALAYA study, KEYNOTE-394 trial, LAUNCH study). Dr Choo

1:18:42 A look to future treatments. Prof Finn

Other programmes of interest